Investigator Details
Kavita Natrajan
Investigation Details
Last Issued Date:
June 29, 2023
Conversion Rate:
0
No. of 483’s Issued :
1
Warning Letters Issued:
0
Detailed Analysis
Approach:
Kavita Natrajan puts a strong emphasis on the responsibility of organizations to protect patient safety. She carefully scrutinizes the data to assess the balancing act between efficacy and safety while paying close attention to any potential risks that may not have been addressed previously.
Profile:
FDA Auditor Kavita Natrajan appears to be an investigator who prioritizes auditing the efficacy and safety of pharmaceutical products. Her observations often highlight any adverse effects or risks related to the medical products used. She demonstrates a thorough understanding of clinical data and has a keen eye for detail when it comes to analyzing a product’s possible side effects or health risks.
Top Process Types:
Facility Name
Product Type
483 Analysis
Converted
Warning Letter
BioMarin Pharmaceutical Inc.
Biologics
